Pulse Biosciences (NASDAQ:PLSE) Posts Earnings Results, Misses Estimates By $0.07 EPS

Pulse Biosciences (NASDAQ:PLSE) posted its earnings results on Thursday. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07), FiscalAI reports. The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative return on equity of 100.22% and a negative net margin of 6,755.78%.

Here are the key takeaways from Pulse Biosciences’ conference call:

• nPulse AF catheter enrollment is ahead of schedule: The pivotal NANOPULSE-AF study surpassed the halfway point with more than 82 evaluable patients, and enrollment is now expected to finish in early October, despite expanding the target from 145 to 164 patients.
• Early clinical and workflow feedback remains highly favorable, with physicians reporting five to seven cases per day and ablation times as short as five to eight minutes. Management believes the resulting throughput and hospital economics could support significant adoption, though pivotal outcomes remain pending.
• European feasibility data for the cardiac catheter showed 96% freedom from AF at one year by 24-hour Holter monitoring, 90% freedom from recurrent AF, flutter, or tachycardia by Kaplan-Meier analysis, and a 1.7% serious adverse event rate across 177 patients. The company remains on track to submit for a CE mark in the second half of 2026 and potentially receive approval around mid-2027.
• Pulse strengthened its balance sheet through $57.5 million of net ATM proceeds, ending Q2 with $101.6 million in cash and extending its runway through key clinical and regulatory milestones. It also established a new $75 million ATM facility and received $1.8 million from warrant exercises.
• Spending and losses increased as the company accelerated clinical and product development, with Q2 GAAP operating expenses rising to $25.7 million and GAAP net loss reaching $24.7 million. Operating cash use rose to $18.7 million, while management expects quarterly non-GAAP expenses to remain near current levels.

Pulse Biosciences Stock Performance

Shares of PLSE stock traded up $4.17 during mid-day trading on Friday, reaching $42.41. 734,091 shares of the company were exchanged, compared to its average volume of 361,024. The business’s 50 day simple moving average is $29.01 and its 200 day simple moving average is $23.64. The company has a market capitalization of $2.94 billion, a P/E ratio of -35.94 and a beta of 1.61. Pulse Biosciences has a fifty-two week low of $12.56 and a fifty-two week high of $45.90.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Pulse Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday. Oppenheimer reissued an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Canaccord Genuity Group assumed coverage on Pulse Biosciences in a research note on Thursday, June 4th. They set a “buy” rating and a $32.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $32.33.

Insider Buying and Selling at Pulse Biosciences

In related news, CEO Paul A. Laviolette acquired 15,000 shares of Pulse Biosciences stock in a transaction on Monday, May 11th. The shares were purchased at an average cost of $19.69 per share, for a total transaction of $295,350.00. Following the purchase, the chief executive officer directly owned 15,000 shares of the company’s stock, valued at $295,350. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert W. Duggan acquired 660,233 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $19.69 per share, with a total value of $12,999,987.77. Following the completion of the acquisition, the director owned 48,211,433 shares in the company, valued at $949,283,115.77. This represents a 1.39% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 74.00% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in Pulse Biosciences during the first quarter valued at approximately $323,000. Creative Planning grew its position in shares of Pulse Biosciences by 26.3% in the 2nd quarter. Creative Planning now owns 18,971 shares of the company’s stock worth $286,000 after acquiring an additional 3,951 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Pulse Biosciences by 57.7% in the 2nd quarter. Legal & General Group Plc now owns 22,415 shares of the company’s stock valued at $338,000 after acquiring an additional 8,197 shares during the last quarter. Norges Bank bought a new stake in shares of Pulse Biosciences in the 2nd quarter valued at approximately $302,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Pulse Biosciences during the 2nd quarter valued at approximately $158,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.